Why Aldeyra Therapeutics' Shares Are Soaring Today?

  • Aldeyra Therapeutics Inc's ALDX Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint.
  • Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer test responder proportions after a single day of dosing. 
  • The Schirmer test, a measure of ocular tear production, is the dry eye disease objective sign most commonly utilized for drug approval.
  • Related: Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness.
  • A Type B Pre-NDA meeting will be held with the FDA in Q3 of 2022, followed by a potential NDA submission, pending enrollment in the ongoing 12-month safety trial and results from a dry eye chamber crossover trial. 
  • Enrollment in the crossover dry eye disease trial is complete, and results are expected in Q3 of 2022. 
  • Price Action: ALDX shares are up 12.2% at $3.60 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsdry eye diseasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!